Additionally, pancreatic cancer patients with elevated PRODH expression had a shorter median overall survival than those with lower PRODH expression, highlighting the potential prognostic value of these enzymes in pancreatic cancer. This evidence concerns the gene PRODH and pancreatic neoplasm.